CYTEK BIOSCIENCES INC (CTKB)
Health Care · Life science tools and reagents · NASDAQ
Cytek Biosciences provides advanced full-spectrum flow cytometry and single-cell analysis tools that enable researchers to perform high-resolution, multi-dimensional phenotyping.
What CYTEK BIOSCIENCES INC does
Cytek Biosciences is a cell analysis solutions company that provides instruments, reagents, and software for biomedical research and clinical applications. Its core technology, Full Spectrum Profiling (FSP), allows for high-dimensional, single-cell analysis by capturing the full range of light emissions from fluorescent tags. The company also offers conventional flow cytometry and imaging systems under the Amnis and Guava brands.
Recent developments
In Q2 2026, the company launched the Cytek Borealis 7-laser flow cytometer and introduced new configurations for the Cytek Aurora Evo system. Additionally, management updated its full-year 2026 revenue guidance to a range of $207 million to $212 million, raising the midpoint by $1 million.
From CYTEK BIOSCIENCES INC's filing of 2026-08-05.
Themes: cell analysis, flow cytometry, single-cell analysis, immunotherapy research, biomedical discovery, life science tools
Fundamentals
- Price$5.50 as of 2026-10-21 close
- Market cap$715M as of 2026-07-31 (share count; price 2026-10-21)
- 1-year return+31.9% 2025-10-21 close $4.17 → 2026-10-21 close $5.50
- P/En/a negative earnings
- Net margin-33.0% FY2025, SEC XBRL
- Gross margin+51.8% FY2025, SEC XBRL
- ROE-19.5% FY2025, SEC XBRL
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing reports debt under a line we do not read, so a total would be understated.
- Revenue growth (YoY)+0.5% FY2025, SEC XBRL
- Revenue CAGR (3y)+7.1% SEC XBRL
- Beta1.21 as of 2026-09-03
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How CTKB compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Revenue | Gross profit | Operating income | Net income | Operating cash flow | Capex |
|---|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | $48M | $28M | -$11M | -$12M | $1M† | $2M† |
| Q1 FY2026 2026-03-31 | $44M | $21M | -$18M | -$19M | -$3M | $2M |
| Q4 FY2025 2025-12-31 | $62M† | $33M† | -$6M† | — | -$771000† | $1M† |
| Q3 FY2025 2025-09-30 | $52M | $28M | -$9M | — | -$4M† | $657000† |
| Q2 FY2025 2025-06-30 | $46M | $24M | -$11M | -$6M | $108000† | $2M† |
| Q1 FY2025 2025-03-31 | $41M | $20M | -$15M | -$11M | -$125000 | $849000 |
| Q4 FY2024 2024-12-31 | $57M† | $34M† | $3M† | — | $2M† | $894000† |
| Q3 FY2024 2024-09-30 | $52M | $29M | -$4M | — | $13M† | $1M† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$74M
- Total debtnot shown the filing reports its long-term debt in a form we do not read yet
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How CYTEK BIOSCIENCES INC looks technically
CYTEK BIOSCIENCES INC (CTKB) is trading 18.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 24 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 4 trading days ago.
Trend
9
| Distance from the 200-day | it is trading 18.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +18.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $5.11 | $5.11 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $4.66 | $4.66 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five; the labelling fails if price closes below 5.045. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 5 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 24 trading days ago — a "golden cross", a bullish long-term signal | 24 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 18.1% above | +18.1% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 18.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 55.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($5.04 to $6.21) — its "stochastic" reading is 39 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 39.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $6.21 | $6.21 |
|---|---|---|
| From the 52-week high | it is 11.4% below its 52-week high (its highest price of the past year) | -11.4% |
| Above the 52-week low | it is 66.2% above its 52-week low (its lowest price of the past year) | +66.2% |
| Below the 52-week high | it is 11.4% below its highest point of the past year | 11.4% |
| Since a 20-day breakout | it made a new 20-day low about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 13 trading days ago | 13 sessions |
| All-time high | its highest closing price on record is $28.69 (set on 2021-09-15) | $28.69 |
| Given back of the 52-week move | over the past year its closes ranged ($3.35 to $6.09), and it has given back roughly a quarter of its rise from last year’s low — 22% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $4.31 to $4.40. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 21.6% |
| From the all-time high | it is 80.8% below its all-time high | -80.8% |
| Nearest price level | it is trading 3.4% below a resistance level at $5.68 — a price it turned at twice since 2024-11-19, most recently on 2025-02-07. Since 2024-10-21 it has 9 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +3.4% |
| All-time low | its lowest closing price on record is $2.37 (set on 2025-05-23) | $2.37 |
| Above the all-time low | it is 132.1% above its all-time low | +132.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 44th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2671 between its high and its low — about 4.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2671 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.05 and $6.04 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.05 – $5.55 – $6.04 |
| Typical daily range (% of price) | its price moves about 4.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.9% |
| Stretch from the 200-day average | it is trading 3.2 daily ranges above its 200-day average price (18.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.72× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a hammer | 9 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 9 sessions ago |
|---|---|---|
| Since a bearish engulfing | 3 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-21 1.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -1.5% |
|---|---|---|
| Gap filled | a 2.3% gap down opened on 2026-10-13 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 6 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +4.76% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 4.2 percentage points (the stock gained 4.2% while the market lost 0.1%) | +4.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 17.0 percentage points (the stock gained 20.4% while the market gained 3.3%) | +17.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 9.0 percentage points (the stock gained 18.8% while the market gained 9.8%) | +9.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 16.7 percentage points (the stock gained 31.9% while the market gained 15.2%) | +16.7% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.5% of the share price. | +17.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 19% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $4.61 — a volume-weighted average of daily closes over 197 sessions, not a true tick-by-tick VWAP. | +19.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $5.16 — a volume-weighted average of daily closes over 55 sessions, not a true tick-by-tick VWAP. | +6.5% |
Price levels it has turned at before
CTKB last closed at $5.50 on 2026-10-21. Since 2024-10-21 it has turned at 9 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.68 | Resistance | 3.4% above the last close | turned there twice · 2024-11-19 to 2025-02-07 |
| $6.03 | Resistance | 9.6% above the last close | turned there three times · 2024-12-20 to 2026-01-12 |
| $4.91 | Support | 10.8% below the last close | turned there four times · 2025-01-31 to 2026-08-14 |
| $6.20 | Resistance | 12.6% above the last close | turned there twice · 2025-11-17 to 2026-10-06 |
| $4.75 | Support | 13.6% below the last close | turned there four times · 2026-03-24 to 2026-07-16 |
| $4.59 | Support | 16.6% below the last close | turned there three times · 2025-03-10 to 2026-03-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 5 of five.
This labelling fails — stops being a possible reading at all — if it closes below $5.04.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $5.59 and $6.49 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 5 trading days, since 2026-10-15.
Read from daily closes as of 2026-10-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Trading above the 50-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-10-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (2.25 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$5.56 range $4.75 – $7.50; median $5.00
Analyst estimates, as of 2026-10-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Dependence on a limited number of product offerings and the inherent challenges of predicting sales cycles for high-value instruments.","Reliance on single-source or sole-source suppliers for critical components, which may impact supply chain stability.","Exposure to various operational, regulatory, and economic risks associated with significant international business operations."]
What changed in the latest 10-Q
AI-assisted comparison of CTKB's 10-Q filed 2026-08-05 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-05) reports total revenue for the three and six months ended June 30, 2026 of $48.1 million and $92.3 million, respectively.
- Newer filing (2026-08-05) reports a 6% increase in revenue for both the three and six months ended June 30, 2026 compared to the three and six months ended June 30, 2025 of $45.6 million and $87.1 million, respectively.
- Newer filing (2026-08-05) states revenue from direct sales represented 69% and 69% of total revenue for the three and six months ended June 30, 2026, respectively.
- Newer filing (2026-08-05) states revenue from direct sales represented 73% and 73% of total revenue for the three and six months ended June 30, 2025, respectively.
- Newer filing (2026-08-05) states revenue from distributors represented 31% and 31% of total revenue for the three and six months ended June 30, 2026, respectively.
- Newer filing (2026-08-05) states revenue from distributors represented 27% and 27% of total revenue for the three and six months ended June 30, 2025, respectively.
- Newer filing (2026-08-05) reports research and development expenses of $9.7 million and $19.3 million for the three and six months ended June 30, 2026, respectively.
- Newer filing (2026-08-05) reports research and development expenses of $8.8 million and $18.6 million for the three and six months ended June 30, 2025, respectively.
- Newer filing (2026-08-05) reports sales and marketing expenses of $13.2 million and $24.8 million for the three and six months ended June 30, 2026, respectively.
- Newer filing (2026-08-05) reports sales and marketing expenses of $12.1 million and $24.6 million for the three and six months ended June 30, 2025, respectively.
- Newer filing (2026-08-05) reports net loss of $12.2 million and $31.0 million for the three and six months ended June 30, 2026, respectively.
- Newer filing (2026-08-05) reports net loss of $5.6 million and $17.0 million for the three and six months ended June 30, 2025, respectively.
- Newer filing (2026-08-05) describes the change in net loss for the three and six months ended June 30, 2026 as resulting primarily from an increase in revenues and gross profit as well as an increase in operating expenses.
- Newer filing (2026-08-05) text includes page break marker with page number 32.
- Removed:
- Older filing (2026-05-07) states manufacturing facilities include Seattle, Washington; newer filing omits Seattle, Washington from the list of manufacturing facilities (Fremont, California; Wuxi, China; and Singapore).
- Older filing (2026-05-07) reports total revenue for the three months ended March 31, 2026 of $44.1 million, representing a 6% increase compared to revenue for the three months ended March 31, 2025 of $41.5 million.
- Older filing (2026-05-07) states revenue from direct sales represented 69% and 72% of total revenue for the three months ended March 31, 2026 and 2025, respectively.
- Older filing (2026-05-07) states revenue from distributors represented 31% and 28% of total revenue for the three months ended March 31, 2026 and 2025, respectively.
- Older filing (2026-05-07) reports research and development expenses of $9.6 million and $9.7 million for the three months ended March 31, 2026 and 2025, respectively.
- Older filing (2026-05-07) reports sales and marketing expenses of $11.6 million and $12.5 million for the three months ended March 31, 2026 and 2025, respectively.
- Older filing (2026-05-07) reports net loss of $18.9 million and $11.4 million for the three months ended March 31, 2026 and 2025, respectively.
- Older filing (2026-05-07) describes the change in net loss for the three months ended March 31, 2026 as resulting primarily from a slight increase in revenues and gross profit, offset by higher operating expenses.
- Older filing (2026-05-07) includes the sentence: "We intend to continue increasing our workforce in line with our growth."
- Older filing (2026-05-07) includes a 'Recurring revenues' paragraph beginning with "We believe our expanding installed base of instruments to new and existing customers will provide us with greater leverage to drive pull-through for reagent and service revenue, which are recurring by nature..." The newer filing excerpt does not include this paragraph (newer text is truncated and does not show the paragraph following 'Global customer adoption').
- Older filing (2026-05-07) text includes page break marker with page number 31.
- Reworded:
- Revenue reporting periods changed: older filing reports three months ended March 31, 2026 vs. three months ended March 31, 2025; newer filing reports three and six months ended June 30, 2026 vs. three and six months ended June 30, 2025.
- Manufacturing facility list changed: older filing lists Fremont, California; Wuxi, China; Seattle, Washington; and Singapore. Newer filing lists Fremont, California; Wuxi, China; and Singapore.
- Net loss explanation wording changed from 'a slight increase in revenues and gross profit, offset by higher operating expenses' (older) to 'an increase in revenues and gross profit as well as an increase in operating expenses' (newer).
- Older filing includes sentence about increasing workforce in line with growth under 'Global customer adoption'; newer filing excerpt does not include this sentence (text may be truncated).
- Newer filing excerpt ends mid-sentence in the 'Global customer adoption' paragraph with 'to support glob'; older filing continues with 'global expansion and drive revenue growth...' and includes the 'Recurring revenues' section.
- Notes:
- The newer filing excerpt is truncated and ends mid-sentence ('to support glob'), so any content after that point in the older filing that is absent from the newer excerpt cannot be definitively characterized as removed from the newer filing.
- The older filing excerpt ends after the 'Recurring revenues' paragraph begins; the full older MD&A may contain additional content beyond the provided excerpt.
- Both excerpts include page break/table of contents markers, which are formatting artifacts rather than substantive disclosures.
Risk Factors
- Reworded:
- In the newer filing (2026-08-05), the text 'immediately follows this risk factor summary' appears directly after 'Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face,' with a page break (\"43\" / 'Table of Contents') inserted between the phrase and 'immediately follows', whereas in the older filing (2026-05-07) the phrase 'immediately follows this risk factor summary' appears directly after the same wording with no intervening page break.
- Notes:
- The provided newer text is truncated mid-sentence (ending with 'results of'), as is the older text, so changes after that point cannot be assessed.
- Page number artifacts (e.g., '43', '42', 'Table of Contents' placements) differ between the two excerpts, which may reflect document formatting rather than substantive content changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CTKB — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CTKB as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 14,753,389
- Reported value $65,357,513
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CTKB's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CTKB had 5,215,595 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
CTKB had 4.01% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.13 days to cover at the same settlement.
- Reported short interest (shares) 5,215,595
- Short interest (% of shares outstanding) 4.01%
- Prior settlement (shares) 5,242,079
- Reported change -0.51%
- Days to cover (reported) 3.13
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Becton, Dickinson and Company (BDX)
- Thermo Fisher Scientific (TMO)
- Bio-Rad Laboratories (BIO)
- Danaher (DHR)
- Sony Group (SONY)
- Agilent Technologies (A)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CTKB vs…
Frequently asked questions
What does CYTEK BIOSCIENCES INC (CTKB) do?
Cytek Biosciences is a cell analysis solutions company that provides instruments, reagents, and software for biomedical research and clinical applications. Its core technology, Full Spectrum Profiling (FSP), allows for high-dimensional, single-cell analysis by capturing the full range of light emissions from fluorescent tags. The company also offers conventional flow cytometry and imaging systems under the Amnis and Guava brands.
What sector is CYTEK BIOSCIENCES INC (CTKB) in?
CYTEK BIOSCIENCES INC (CTKB) is classified in the Health Care sector. Its industry is Life science tools and reagents. It trades on NASDAQ.
Who are CYTEK BIOSCIENCES INC's (CTKB) competitors?
Notable peers of CYTEK BIOSCIENCES INC (CTKB) include Becton, Dickinson and Company, Thermo Fisher Scientific, Bio-Rad Laboratories, Danaher and Sony Group. This peer set is informational only — not financial advice.
Is CYTEK BIOSCIENCES INC (CTKB) overbought or oversold right now?
CYTEK BIOSCIENCES INC (CTKB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-10-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CTKB come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.